MAPK3 and acute lymphoblastic leukemia: Our data show that inhibition of PKC’s activity using ENZ significantly reduced the induction of p-ERK1/2 in pevonedistat-treated ALL cells (Figure 1B), establishing a cause-effect relationship between increased expression (activation) of p-PKCα/β II and MEK-ERK pathway activation in pevonedistat-treated ALL cells.